Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

Stock Information for Acer Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acer Therapeutics Inc.

BIOLASE Voluntarily Initiates Chapter 11 Proceedings
BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
BIOLASE Announces Delisting from Nasdaq
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.